EHA

Eye Health America Announces Newest Acquisition of Loris Eye Associates

Retrieved on: 
Thursday, February 1, 2024
Optical, Health, Surgery, Practice Management, Partnership, Contact, Southeastern United States, Associate, MD, Glaucoma, LEA, OD, Patient, Pediatrics, Retina, CCFS, Abdominal ultrasonography, Physician, EHA, Hospital

Welcome Dr. Tracy Ray and Loris team to our exceptional roster of eye care professionals.

Key Points: 
  • Welcome Dr. Tracy Ray and Loris team to our exceptional roster of eye care professionals.
  • Founded in 2018 by LLR Partners, Clemson Eye, and The Eye Associates, EHA is led by experienced eye care leadership, providing superior support to partner practices.
  • Eye Health America (EHA) is a leading eyecare provider focused on partnering with culturally aligned ophthalmology practices, optometry practices and ambulatory surgery centers across the Southeast U.S. to provide superior strategic, financial, and operational support for best-in-class eye care.
  • Member practices include Clemson Eye, Piedmont Surgery Center, EHA Surgery Center Seneca, The Surgery & Laser Center, Carolinas Centers for Sight, Florence Surgery and Laser Center, Southeast Retina Center, Augusta Retina Laser Surgicare, The Eye Associates, The Eye Associates Surgery Center, EHA Surgery Center Sarasota, Eye Centers of Florida, Surgicare Center, Updegraff Laser Vision, Tampa Bay Eye Surgery Center, West Georgia Eye Care Center, Eye Surgery Center of West Georgia, and many other top eyecare providers.

Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company's Proprietary Platform, for the Treatment of Relapsed/Refractory Multiple Myeloma.

Retrieved on: 
Monday, January 29, 2024
The Lancet, Hope, CMC, Patient, ISS, MRD, Therapy, GPRC5D, ASCO, EMD, CRS, IND, Food, Multiple myeloma, EHA, FDA, Investigational New Drug, BCMA, POLARIS, NMPA, Pharmaceutical industry

OriCAR-017 is a chimeric antigen receptor (CAR) T cell therapy targeting GPRC5D.

Key Points: 
  • OriCAR-017 is a chimeric antigen receptor (CAR) T cell therapy targeting GPRC5D.
  • The therapy leverages Oricell's proprietary platforms including Ori®Ab antibodies, Ori®CAR construct and unique CMC know-how to achieve optimal binding and superior persistence and anti-tumor efficacy out of rejuvenated CAR-T cells.
  • The IND enables Oricell to initiate the clinical development for OriCAR-017 in the US immediately.
  • "The evidenced superior safety, efficacy and durability profile of OriCAR-017 is truly exciting and will significantly benefit multiple myeloma patients on a global scale.

Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar

Retrieved on: 
Monday, December 11, 2023
SCD, Cleveland Clinic, Sickle cell disease, Șaeș, Division, EHA, Editas Medicine, Anemia, Data, Fetal hemoglobin, MD, Society, Clinical trial, Busulfan, Blood, Event, ASH, European Hematology Association, Patient, TDT, Safety, Senior, Pharmaceutical industry

The total dataset of 17 treated patients includes 12 additional patients since the data presentation at the European Hematology Association (EHA) Annual Congress and in a Company-sponsored webinar this past June.

Key Points: 
  • The total dataset of 17 treated patients includes 12 additional patients since the data presentation at the European Hematology Association (EHA) Annual Congress and in a Company-sponsored webinar this past June.
  • Editas Medicine will present the RUBY and EdiTHAL trial data today at 1 p.m.
  • The data will also be presented in a poster presentation at the American Society of Hematology (ASH) Annual Meeting in San Diego, CA, at 6:00 p.m. PT (9:00 p.m.
  • Presenting Author: Rabi Hanna, M.D., Department of Pediatric Hematology Oncology and Blood and Marrow Transplantation, Cleveland Clinic Children’s, Cleveland, OH, United States

Notable Labs Announces JCO Precision Oncology Publication Demonstrating PPMP Potential to Identify Novel Drug Combinations in JMML

Retrieved on: 
Thursday, November 9, 2023
EHA, CD38, Associate, UCSF Benioff Children's Hospital, European Hematology Association, Juvenile myelomonocytic leukemia, Transplant, Disease, Database, UCSF, Patient, ASCO, Hematopoietic stem cell transplantation, APL, AZA, Blood, Cytarabine, FLA, Cancer, Tretinoin, Acute promyelocytic leukemia, Trial of the century, Malignancy, Society, Physician, Cell, Bone marrow, Drug combination, Pharmaceutical industry, JMML

FOSTER CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”) (Nasdaq: NTBL), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced the publication of data from an ex vivo study demonstrating the potential for its Predictive Precision Medicine Platform (PPMP) to identify more effective pre-hematopoietic stem cell transplantation (pre-HSCT) regimens for the treatment of juvenile myelomonocytic leukemia (JMML) in the November 9th Issue of the American Society of Clinical Oncology (ASCO) Journal JCO Precision Oncology. Part of this data was recently presented at the European Hematology Association (EHA) Hybrid Congress held in Frankfurt, Germany on June 8 – 15, 2023. Details of that presentation can be found on the Company’s website at https://notablelabs.com/.

Key Points: 
  • JMML is a rare, aggressive pediatric malignancy for which curative treatment is restricted to hematopoietic stem cell transplantation.
  • Pre-HSCT therapies, i.e., therapies prior to transplantation, include moderately intensive chemotherapy (particularly fludarabine and cytarabine in combination (FLA)) and azacytidine (AZA) monotherapy.
  • Applying its proprietary PPMP technology to blood or bone marrow samples from JMML patients, Notable screened 130 drug combinations and discovered that 27 of these combinations (26 dual-, 1 triple-combination) were more effective ex vivo than the components of these combinations tested individually.
  • “This publication marks the culmination of a multi-year collaboration between UCSF and Notable Labs,” remarked Dr. Stieglitz.

Eye Health America Announces Newest Acquisition of Medical, Laser, & Surgical Care of Vision and Eye Disease

Retrieved on: 
Thursday, November 30, 2023
Surgery, Other Health, Health, Practice Management, Optical, EHA, Surgical Care Affiliates, Abdominal ultrasonography, Southeastern United States, Multimedia, FACS, Partnership, Growth, Physician, Eye, MD

Eye Health America (EHA), the integrated eyecare platform in the Southeastern United States, announces its latest partnership with Medical, Laser, & Surgical Care of Vision and Eye Diseases (MLSCVED), marking its 23rd strategic collaboration since 2018.

Key Points: 
  • Eye Health America (EHA), the integrated eyecare platform in the Southeastern United States, announces its latest partnership with Medical, Laser, & Surgical Care of Vision and Eye Diseases (MLSCVED), marking its 23rd strategic collaboration since 2018.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20231127828514/en/
    Located in Venice, FL, MLSCVED, led by Dr. Mark Johnson, MD, FACS, has been delivering ophthalmic services since 1999.
  • Founded in 2018 by LLR Partners, Clemson Eye, and The Eye Associates, EHA is led by experienced eye care veterans, providing superior support to partner practices.

InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of Orelabrutinib for the Treatment of ITP in China

Retrieved on: 
Friday, October 27, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, HKEX, SSE, Incidence, European Hematology Association, Entrepreneurship, Bruise, Bleeding, Phase, Risk, ITP, Cancer, BTK, Patient, EHA, Pharmaceutical industry

Orelabrutinib, a novel BTK inhibitor developed by InnoCare, has high target selectivity and a good safety profile, which makes it suitable for the development of various autoimmune diseases.

Key Points: 
  • Orelabrutinib, a novel BTK inhibitor developed by InnoCare, has high target selectivity and a good safety profile, which makes it suitable for the development of various autoimmune diseases.
  • Currently, there are no BTK inhibitors approved for the treatment of ITP in the world.
  • Orelabrutinib has consistently demonstrated a promising efficacy and safety profile in treating autoimmune diseases, including ITP.
  • It is expected that orelabrutinib has potential to provide a better treatment option for ITP patients.

Shaare Zedek Medical Center Uses SOPHiA GENETICS to Advance Research of Myeloid Disorders

Retrieved on: 
Friday, September 29, 2023
Database, Shaare Zedek Medical Center, European Hematology Association, Classification, NGS, Research, Disorder, Sophia, Sophia Genetics, Platform, GENETICS, EHA, Medicine, Artificial intelligence, Shaare Zedek, Pharmaceutical industry, Nursing, Medical device

BOSTON and ROLLE, Switzerland, Sept. 29, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Shaare Zedek, the largest multi-disciplinary medical center in Jerusalem, is now live on the SOPHiA DDM™ Platform. The Platform will enable Shaare Zedek to advance its insights the treatment of myeloid disorders and further develop the application of precision medicine.

Key Points: 
  • The Platform will enable Shaare Zedek to advance its insights the treatment of myeloid disorders and further develop the application of precision medicine.
  • Myeloid disorders affect millions of people worldwide, and while there are various types and classification of these disorders, collectively all myeloid disorders originate from hematopoietic disruptions in the myeloid lineage1.
  • Shaare Zedek Medical Center has been providing top-level medical research and care for the people of Jerusalem since 1902.
  • With the SOPHiA DDM™ Platform, Shaare Zedek Medical Center will retain complete ownership of its database, supporting the research team as it continues to increase its expertise.

Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma

Retrieved on: 
Tuesday, September 26, 2023
IIT, CD19, European Hematology Association, Multiple myeloma, Survival, Cancer, Pharmacokinetics, Trial of the century, ASCO, American Society of Clinical Oncology, Patient, Graceling, SAN, Autoimmune disease, EHA, RRMM, Society, Neurotoxicity, ORR, BCMA, Safety, Pharmaceutical industry, Medical device

The Phase 1b portion of the open-label multi-center trial has been initiated and will be conducted at several top medical centers in the United States.

Key Points: 
  • The Phase 1b portion of the open-label multi-center trial has been initiated and will be conducted at several top medical centers in the United States.
  • The Phase 2 portion is intended to evaluate the efficacy of GC012F in RRMM patients and further characterize the safety of GC012F.
  • “Gracell has amassed a body of compelling evidence supporting the dual-targeting approach of GC012F for treatment of RRMM.
  • “Dosing the first patient in the Phase 1b portion of the U.S. trial is another important step toward validating this treatment for RRMM patients.

Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty

Retrieved on: 
Friday, September 22, 2023
AMGN, KRAS, Gastrointestinal cancer, Amgen, Optimism, DOR, National Institutes of Health, Bangladesh Technical Education Board, Congress, Patient, Risk, Corr, H. Lee Moffitt Cancer Center & Research Institute, News, Disease, Carcinoma, Oncolytics Biotech, European Hematology Association, Hope, Lung cancer, ONC, Hematology, TSX, Bone marrow, BTC, The Lancet, FDA, Polycythemia, NIH, Safety, Docetaxel, Abstract, Eye, Cancer, NSCLC, PFS, Psoriasis, MD Anderson Cancer Center, Breakthrough therapy, Colorectal cancer, University, Cancer Moonshot, Therapy, ORR, Partnership, CRC, Progression-free survival, RBC Capital Markets, OS, Paclitaxel, SCLC, ASCO, Pelareorep, EHA, Jazz Pharmaceuticals, Breast cancer, Pharmaceutical industry, Birth control, Vaccine, Medical imaging, Protagonist, Research

VANCOUVER, British Columbia, Sept. 22, 2023 /PRNewswire/ -- USA News Group - Despite the potential federal funding challenges due to the recent debt ceiling deal, optimism in the battle against cancer persists, thanks in large part to the audacious "Cancer Moonshot" initiative. This ambitious plan, aimed at halving cancer rates within the next quarter-century, continues to fuel hope even as concerns about the stability of National Institutes of Health (NIH) funding arise. In these turbulent times, the resilience and ingenuity of the biotech sector provide a beacon of hope. For instance, Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Zymeworks Inc. (NASDAQ: ZYME), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Protagonist Therapeutics, Inc. (NASDAQ: PTGX), and Amgen Inc. (NASDAQ: AMGN), have each demonstrated inspiring progress and unwavering commitment in advancing cancer treatments, highlighting their vital role in the future of cancer therapy.

Key Points: 
  • The oral presentation shared at the event described how they've been testing a treatment for advanced breast cancer, and it's looking very promising.
  • The treatment combines Oncolytics' flagship drug, pelareorep, with a well-known cancer medicine, paclitaxel.
  • Pelareorep is a unique drug that targets and kills cancer cells by making them self-destruct while leaving healthy cells unharmed.
  • It even lowered the risk of the cancer getting worse by a significant 71% compared to just using paclitaxel.

Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty

Retrieved on: 
Friday, September 22, 2023
AMGN, KRAS, Gastrointestinal cancer, Amgen, Optimism, DOR, National Institutes of Health, Bangladesh Technical Education Board, Congress, Patient, Risk, Corr, H. Lee Moffitt Cancer Center & Research Institute, News, Disease, Carcinoma, Oncolytics Biotech, European Hematology Association, Hope, Lung cancer, ONC, Hematology, TSX, Bone marrow, BTC, The Lancet, FDA, Polycythemia, NIH, Safety, Docetaxel, Abstract, Eye, Cancer, NSCLC, PFS, Psoriasis, MD Anderson Cancer Center, Breakthrough therapy, Colorectal cancer, University, Cancer Moonshot, Therapy, ORR, Partnership, CRC, Progression-free survival, RBC Capital Markets, OS, Paclitaxel, SCLC, ASCO, Pelareorep, EHA, Jazz Pharmaceuticals, Breast cancer, Pharmaceutical industry, Birth control, Vaccine, Medical imaging, Protagonist, Research

VANCOUVER, British Columbia, Sept. 22, 2023 /PRNewswire/ -- USA News Group - Despite the potential federal funding challenges due to the recent debt ceiling deal, optimism in the battle against cancer persists, thanks in large part to the audacious "Cancer Moonshot" initiative. This ambitious plan, aimed at halving cancer rates within the next quarter-century, continues to fuel hope even as concerns about the stability of National Institutes of Health (NIH) funding arise. In these turbulent times, the resilience and ingenuity of the biotech sector provide a beacon of hope. For instance, Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Zymeworks Inc. (NASDAQ: ZYME), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Protagonist Therapeutics, Inc. (NASDAQ: PTGX), and Amgen Inc. (NASDAQ: AMGN), have each demonstrated inspiring progress and unwavering commitment in advancing cancer treatments, highlighting their vital role in the future of cancer therapy.

Key Points: 
  • The oral presentation shared at the event described how they've been testing a treatment for advanced breast cancer, and it's looking very promising.
  • The treatment combines Oncolytics' flagship drug, pelareorep, with a well-known cancer medicine, paclitaxel.
  • Pelareorep is a unique drug that targets and kills cancer cells by making them self-destruct while leaving healthy cells unharmed.
  • It even lowered the risk of the cancer getting worse by a significant 71% compared to just using paclitaxel.